Skip to main content
Probity GlobalPharma

Export Region

Europe & New Markets

Future expansion — EU-GMP pathway development and structured entry into regulated markets.

In development
Status
2027
Target entry
Open
Partnerships

Our operations in Europe & New Markets

Our next horizon is regulated-market entry. We are developing EU-GMP-approved sourcing partnerships and building the pharmacovigilance and serialization infrastructure that CE-regulated and other stringent markets require. We welcome conversations with EU, UK and Australian partners planning 2027-and-beyond portfolios.

Registration

EU-GMP and TGA-approved site partnerships under development; decentralized-procedure and national-filing strategies scoped with European regulatory counsel.

Products in Demand

Initial focus on high-volume solid orals and selected nutraceutical lines where Indian manufacturing offers durable cost advantage under stringent-authority oversight.

Market Information

Regulated markets demand years of preparation and reward it with stability. We are making that investment now — partners who join the pathway early help shape the portfolio.

Import process

  1. 1EU-GMP / stringent-authority site qualification
  2. 2Dossier development to EU-CTD / TGA standards
  3. 3Batch-release and QP arrangements with EU partners
  4. 4Serialization (FMD) and pharmacovigilance systems

Countries we serve

European Union (pathway)United Kingdom (pathway)Australia (pathway)New Zealand (pathway)

Enquire about Europe & New Markets

Tell us your country and products — we'll map the registration and supply route.

We reply within one business day. Your details stay confidential.

Ready to discuss your market?

Send us your product list, tender specification or private-label brief. A senior export manager — not a chatbot — replies within one business day.

Or message our export desk on WhatsApp